SARTORIUS AG O.N.
Commented by Fabian Lorenz on September 16th, 2024 | 07:00 CEST
Big news at BioNTech! Soon also at Nyxoah? What about Sartorius?
The more than 10% jump in BioNTech's share price at the beginning of the week surprised many investors. Was this the starting signal for a sustained upward trend? The biotech company will publish important data in the coming days. Nyxoah is also getting ready for the big bang. The medical technology company is on the verge of entering the US market with its high-tech product. The Belgian company is fully financed to tap into the world's largest healthcare market. Are Nyxoah shares about to take off? The Sartorius share has started a countermovement in recent days. Is there more to come for the share price?
Read
Commented by Stefan Feulner on January 3rd, 2023 | 08:30 CET
Growing optimism at Deutsche Bank, Alerio Gold and Sartorius
The volatile and weak stock market year 2022 is history, but the issues with rising inflation combined with fears of recession as well as the uncertainties in geopolitics with existing and threatening conflicts in Ukraine and Taiwan remain. Thus, at least the high volatility is likely to continue. Despite all the imponderables, many experts see opportunities for a thoroughly positive stock market year. In the gold sector, too, new price targets beyond 2000 are already being passed around. Many shares from this sector therefore offer attractive long-term entry opportunities at a reduced level.
Read
Commented by Nico Popp on January 31st, 2022 | 11:56 CET
MedTech with billion-dollar potential: Siemens Healthineers, Perimeter Medical Imaging, Sartorius
When we think of medical technology, we often think of the big players like Siemens Healthineers or the Fresenius Group. But the MedTech sector is characterized mainly by small and medium-sized companies. This is shown by a survey conducted by the German Medical Technology Association (BVMed). The experts have seen rising sales for years in this very diverse sector. Reason enough to shed light on a promising market from an investor's perspective. We present three companies and their shares.
Read
Commented by Stefan Feulner on October 21st, 2021 | 12:17 CEST
Sartorius, Defence Therapeutics, QIAGEN - Still long potential
Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.
Read
Commented by Nico Popp on September 15th, 2021 | 12:17 CEST
Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase
The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.
Read
Commented by Nico Popp on June 28th, 2021 | 11:15 CEST
Pfizer, Sartorius, Defence Therapeutics: Health as an investment opportunity
Tremendous opportunities lie dormant in biotech companies. New therapeutic approaches are suitable for fighting civilization diseases such as cardiovascular problems, cancer and Alzheimer's. In recent years, there has been a whole series of scientific breakthroughs. Some studies have shown phenomenal possibilities. It is now up to innovative companies to turn laboratory findings into practical clinical results. For shareholders, the opportunities are plentiful.
Read